Remicade (infliximab) is an anti-TNF biologic indicated for multiple inflammatory diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The label classifies it as a tumor necrosis factor blocker and describes neutralization of TNF-alpha signaling. U.S. approval was first granted in 1998.
The global biosimilar market is experiencing robust growth, valued at USD 36.79 billion in 2024 and projected to reach USD 282.3 billion by 2035 at a CAGR of 20.35%, driven by patent expirations, cost pressures, and expanding access to biologic therapies.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary on February 18, 2026. Braun brings over 20 years of healthcare experience and facilitated LIXTE's November 2025 acquisition of Liora's assets.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03707535 |
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis |
COMPLETED | PHASE3 |
| NCT03478111 |
CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis |
COMPLETED | PHASE3 |
| NCT02990806 |
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE) |
COMPLETED | PHASE3 |
| NCT02711202 |
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation |
COMPLETED | NA |
| NCT02683564 |
BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study |
UNKNOWN | PHASE3 |
| NCT02539368 |
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease |
COMPLETED | |
| NCT02096861 |
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease |
COMPLETED | PHASE3 |
| NCT01844804 |
A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01) |
COMPLETED | PHASE1 |
| NCT01638715 |
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action |
COMPLETED | PHASE4 |
| NCT01438151 |
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease |
TERMINATED | NA |
